drugset / Trial / NCT00003009
Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer
Phase 1
Terminated
16 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Giving interleukin-2 in different ways may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of inhaled interleukin-2 in treating patients with metastatic or unresectable cancer.
Timeline
- Start
- 1996-02
- Primary completion
- 2000-08
- Completion
- 2000-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Inhaled |